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In response to infection, antigen-specific CD8+ T cells are primed in the T 
cell zone of secondary lymphoid organs and differentiate into cytotoxic effector T 
(TC) cells
1. Concurrently, CD4+ T cells differentiate into follicular helper T (TFH) 
cells that localize to B cell follicles and promote protective antibody responses2. 
During unresolved infections, however, some viruses including human 
immunodeficiency virus (HIV) or Epstein–Barr virus (EBV) escape immune control 
and persist in TFH cells and B cells, respectively
3-8. Exclusion of Tc cells from B 
cell follicles is thought to be a major mechanism of immune evasion9-11. New 
strategies are therefore needed to eradicate infected cells in follicles for a 
permanent cure. Using mouse infection models and human samples, we here 
identify a specialized group of TC cells expressing the chemokine receptor CXCR5 
that can selectively enter B cell follicles and eradicate infected TFH and B cells. 
We demonstrate that differentiation of these cells, which we term follicular 
cytotoxic T (TFC) cells, requires the transcription factors Bcl6, E2A and Tcf1, 
whereas the transcriptional regulators Blimp1, Id3 and Id2 inhibit their 
development. We demonstrate that Blimp1 and E2A directly regulate Cxcr5 
expression, and together with Bcl6 and Tcf1 form a transcriptional circuit that 
guides TFC differentiation. The identification of a follicular subset of TC cells has 
far-reaching implications for developing better strategies for the control of 
infections that target B cells and TFH cells and for the eradication of B cell-derived 
malignancies. 
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Coordinate differentiation of distinct effector populations of TC cells is required for 
efficient elimination of infected or cancerous cells. Differentiation of TC is driven by a 
network of transcription factors, most prominently by T-bet, Blimp1 and Id2, which 
regulate differentiation of effector Tc cells12,13. In addition to the acquisition of cytotoxic 
effector function, migration to the site of infection or tumour growth is a prerequisite for 
efficient function of Tc cells. The entry of Tc cells in lymphoid and non-lymphoid tissues 
is well studied1; however, surprisingly, little is known about the ability of Tc cells to enter 
B cell follicles and control infection at this site. Although some studies suggest that Tc 
cells are excluded from entry into B cell follicles9,11, CXCR5+ CCR7- TC cells were 
reported to position in tonsil B cell follicles14. In line with this finding, we found significant 
numbers of TC cells in B cell follicles of lymph nodes from HIV-infected individuals naïve 
to treatment (Fig. 1A). Importantly, some follicular TC cells localized in close proximity to 
HIV-infected cells (Fig. 1B), suggesting they may play a role in controlling the infection 
in B cell follicles. Localization of T cells is regulated by the expression of multiple 
chemotactic receptors. Naïve T cells express C-C chemokine receptor type 7 (CCR7) 
and localize to the T cell zone. However, upon antigen-stimulation CCR7 is down-
regulated, and CD4+ T cells migrate to the T-B border where they can upregule CXCR5  
and differentiate into TFH cells that enter the B cell follicles
15. We hypothesized that a 
similar mechanism might also govern the follicular positioning of TC cells in infection. 
Indeed, we identified CXCR5 expression in a substantial percentage of CD45RA-CCR7- 
effector TC cells in lymph nodes from HIV-infected individuals (Fig. 1C).  
To examine how Tc cells gain access to B cell follicles during viral infection and 
contribute to virus control, we made use of the DOCILE strain of the lymphocytic 
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choriomeningitis virus (LCMV), which causes a chronic infection in mice that shares 
characteristics with HIV infection16. We also utilized T-cell receptor (TCR) transgenic 
CD8+ T cells (P14) specific for the LCMV epitope gp33-41 (ref. 17), which we transferred 
into recipient mice before LCMV infection. On day 8 post-infection, P14 cells were 
observed not only in the T cell zone but also in B cell follicles where they persisted 
beyond day 21 post-infection (Fig. 1D). We also observed endogenous CD8+ T cells in 
B cell follicles in LCMV-infected mice that did not receive P14 cells (Fig. S1). Both 
transferred P14 cells and endogenous activated TC cells showed minimal expression of 
CCR7 (Fig. S2A). CXCR5 expression was detected on approximately 20% of P14 cells 
and 10% of endogenous LCMV-specific CD8+ T cells (Fig. 1E and S2B). The 
percentage of the CXCR5+ subset amongst the transferred P14 cells increased from 
day 8 to day 15 and remained high at least until day 35 post-infection (Fig. 1F). 
Upregulation of CXCR5 was also detected on OT-I CD8+ T cells that expressed a 
transgenic TCR specific for the ovalbumin (OVA) epitope 257-264 (ref. 18) in mice that 
were infected with OVA-expressing influenza virus or immunized with OVA in complete 
freund's adjuvant (Fig. S3). Importantly, Cxcr5-/- P14 cells were severely impaired in 
their ability to enter B cell follicles in comparison to their wildtype counterparts (Fig. 1G). 
Similar to LCMV and influenza virus, infection of mice with B cell-tropic Murid 
Herpesvirus-4 (MuHV-4) resulted in the generation of CXCR5+ TFC cells (Fig. 1H). 
Finally, CXCR5 expression was also confirmed on human TC cells specific for EBV (also 
known as human herpesvirus 4, HHV-4) in tonsils from individuals previously infected 
with EBV (Fig. 1I). These data demonstrate that CXCR5 is expressed on mouse and 
human TFC cells localized in B cell follicles.  
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LCMV preferentially replicates in myeloid cells, but also infects CD4+ T cells19. 
Intracellular staining with an antibody (VL4) specific to the LCMV nucleoprotein (NP) 
can be used to quantify the amount of viral particles in cells19,20. LCMV-infected mice 
harboured significant numbers of virus-infected CD4+ T cells (Fig. S4). In addition, we 
observed the presence of LCMV in TFH cells in B cell follicles and non-TFH cells in T cell 
zones (Fig. 2A). At day 15 post-infection, TFH cells showed higher infection rates than 
non-TFH cells (Fig. 2B and C), which was confirmed by quantification of LCMV RNA 
(Fig. S5). To test whether TFC cells are essential to specifically control infection of TFH 
cells, we adoptively transferred SMARTA CD4+ T cells expressing a transgenic TCR 
specific for the LCMV epitope gp66-77 (ref. 21), together with either Cxcr5
+/+ or Cxcr5-/- 
P14 cells into mice and infected them with LCMV (Fig. S6A). In order to avoid 
competition with endogenous T cells, we used mice carrying an irrelevant TCR-
transgene (OT-I) as recipients. As expected, upon LCMV infection, SMARTA cells 
differentiated into both TFH and non-TFH cells (Fig. 2D). At day 10 post-infection, 
differentiation of TFH cells, expansion of P14 cells and viral loads in sera and spleens 
were similar between mice that had received either Cxcr5+/+ or Cxcr5-/- P14 cells (Fig. 
S6B-D). Furthermore, the number of non-TFH cells infected with LCMV was similar in 
the two groups (Fig. 2E). In contrast, the frequency of LCMV-infected TFH cells in mice 
that had received Cxcr5-/- P14 cells was about 2-fold higher than that in mice receiving 
Cxcr5+/+ P14 cells (Fig. 2E). In particular, infected TFH cells with high amounts of LCMV 
(NPhigh) were at least 3-fold more abundant in mice that had received Cxcr5-/- P14 cells 
compared to mice that had received wildtype P14 cells (Fig. 2E). Therefore, the lack of 
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TFC cells resulted in selective increase of infection in TFH cells, indicating a specific role 
for CXCR5+ TFC cells in controlling TFH infection. 
The anatomical localization of TFC cells suggested that they would also be able to 
control infected or malignant B cells. To test this idea, we adoptively transferred either 
Cxcr5+/+ or Cxcr5-/- TC cells into recipient OT-I mice, which we subsequently infected 
with MuHV-4 expressing eGFP from an intergenic EF1α promoter to visualize infected 
cells22. At day 9 post-infection, expansion and activation of transferred Cxcr5+/+ or 
Cxcr5-/- TC cells was similar (Fig. S7A, B). However, the frequency of MuHV-4-infected 
B cells in mice that had received Cxcr5-/- TC cells was 4.5-fold higher than that in mice 
that had received Cxcr5+/+ TC cells (Fig. 2F).  Thus, TFC cells contribute to the 
eradication of virus-infected B cells infection. Consistent with the prominent role of CD8 
T cells in controlling nascent B cell lymphoma23, large numbers of CXCR5+ TFC cells 
were detected in B cell lymphoma bearing mice (Fig. S8). Together, these data 
demonstrate that TFC cells are phenotypically and functionally specialized effector Tc 
subset. 
To characterize TFC cells comprehensively at the molecular level, we performed 
transcriptional profiling of CXCR5+ TFC and CXCR5
- non-TFC P14 cells by RNA 
sequencing at day 8 post-infection. Although both populations shared many molecular 
characteristics and differed profoundly from their naïve counterparts, we found 1201 
transcripts that were significantly up or downregulated (≥ 2-fold, P value < 0.05) in TFC 
compared to non-TFC cells and make up the TFC transcriptional signature (Fig. S9 and 
S10). TFC cells expressed lower amounts of transcripts encoding effector molecules 
involved in cytotoxicity, including granzyme A, B, perforin and IFNγ, and exhibited 
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increased expression of genes involved in memory T cell development, including Il7r 
and Sell (encoding CD62L). Furthermore, TFC cells expressed higher amounts of 
transcripts encoding ICOS, Ly108 and CD200 but lower amounts of that encoding 
SLAM (Fig. 3A). Havcr2 and Cd244 (encoding the inhibitory receptors Tim-3 and 2B4) 
were lower in TFC than in non-TFC cells (Fig. 3A), while Pdcd1 (encoding PD-1) was 
expressed in similar amounts. Importantly, we confirmed differential expression of many 
of these molecules at the protein level (Fig. 3B-E and S11A). Notably, TFC cells did not 
express ICOSL, a marker for regulatory CD8+ T cells in B cell follicles that were 
identified in autoimmune diseases24 (Fig. S11B), nor IL-21, the helper cytokine 
produced by TFH cells to support antibody response
2 (Fig. S11C). CXCR5+ TFC P14 
cells executed cytotoxic function, although, consistent with their lower expression of 
some of the cytotoxic molecules, they were less efficient than their CXCR5- 
counterparts (Fig. 3F and S11D).  
While TFC cells expressed similar amounts of Tbx21 (encoding T-bet) and 
Eomesodermin (Eomes) (data not shown), they displayed high expression of the 
transcriptional regulators Bcl6, Tcf7 (encoding Tcf1) and Id3, and low expression of 
Prdm1 (encoding Blimp1) and Id2 (Fig. 3A, 4A,B and S12A,B). Interestingly,  this 
transcriptional profile was similar to that of Tfh cells25-32. Indeed, we found striking 
enrichment of the transcriptial signature of TFC cells within the gene expression 
signature associated with TFH cells, with 67.7% of the upregulated genes and 92.2% of 
the downregulated genes in TFC cells being regulated correspondingly in TFH cells (Fig. 
S13A). Bcl6 plays a key role in TFH biology and is sufficient to drive TFH development
25-
27. Overepression of Bcl6 dramatically increased the expression of CXCR5 on P14 cells 
Page 10 
 
from ~20% to ~60% during LCMV infection (Fig. 4C) and resulted in their dramatically 
increased recruitment to B cell follicles (Fig. 4D). Overexpression of Bcl6 was sufficient 
to recapitulate the TFC phenotype including upregulation of IL-7R, CD62L and ICOS, 
downregulation of granzyme B and Tim-3, and reduced cyototoxic activity in comparison 
to control cells (Fig. S14A-C). Furthermore, overexpression of Bcl6 enhanced the 
expression of Tcf7 and Id3 but inhibited the expression of Prdm1 and Id2 (Fig. S14D). 
Consistent with a critical role for Bcl6 in TFC cell differentiation, Bcl6-deficient P14 cells 
failed to differentiate into TFC cells (Fig. 4E). Therefore, Bcl6 is necessary and sufficient 
to direct the differentiation of TFC cells. Blimp1 has been shown to antagonize TFH 
differentiation25. In line with an important negative regulatory function for Blimp1 in TFC 
differentiation, antigen-specific Blimp1-deficient TC cells showed a marked increase in 
CXCR5 expression (Fig. 4F) and a marked deregulation of  TFC transcriptional signature 
genes (20.2%  upregulated and 25.3% downregulated)33 (Fig. S13B). During TFH 
development, Tcf1 promotes Bcl6 and inhibits Blimp1 expression29-31. In line with a 
similar role in TFC cells, antigen-specific TC cells lacking Tcf1 were severely impaired in 
TFC cell generation (Fig. 4G). Id2 and Id3 are transcriptional regulators that sequester 
E-protein family transcription factors, including E2A, and inhibit CXCR5 expression in 
thymocytes and peripheral CD4+ T cells28,32. Consistent with this notion, loss of Id2 
promoted T cell-intrinsic CXCR5 expression (Fig. 4H). Similarly, lack of Id3 resulted in 
enhanced T cell-intrinsic CXCR5 expression in LCMV-specifc Tc cells, whereas 
overexpression of Id3 in LCMV-specifc Tc cells diminished TFC differentiation (Fig. 4I, 
J). In line with a role for Id proteins in the inhibition of TFC cell generation, Id2 or Id3 
deficient T cells34,35 showed significant deregulation of genes differentially expressed in 
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TFC cells in comparison to non-TFC cells (Fig. S13C,D). Interestingly, while Id3 was 
expressed predominantly in TFC cells, Id2 was highly expressed in non-TFC cells, 
suggesting that limiting E protein activity is critical for the coordinate differentiation of 
both TFC and non-TFC populations.  
Consistent with a critical function for Bcl6 in TFC differentiation, we found 
signficant enrichment of genes bound by Bcl6 among the differentially expressed genes 
in TFC cells (Fig. S15A). However, we did not find evidence for Bcl6 directly regulating 
the expression of CXCR5 (ref. 36,37). In contrast, chromatin immunoprecipitation 
followed by deep-sequencing (ChIP-seq) identified two Blimp1- and two E2A binding 
sites at the Cxcr5 locus (Fig. 4K) that contained the consensus Blimp1- and E2A-
binding motifs, respectively (Fig. S16A). In vivo reporter assays using retroviral 
vectors31 (Fig. S16B) containing either wildtype or mutated Blimp1 binding motifs (Fig. 
S16A), revealed that Blimp1-mediated suppression of Cxcr5 promoter activity was 
abolished when the binding sequence was mutated (Fig. 4L and S16C). In contrast, 
E2A-binding promoted the Cxcr5 promoter-driven transcription; however, this activity 
was largely abolished in the presence of the adjacent Blimp1 binding site (Fig. 4M and 
S16D). We also observed binding of Blimp1 and E2A to Tcf7, Bcl6 and Id3 as well as 
binding of E2A at Id2 (Fig. S17), suggesting that both factors play central roles in the 
transcriptional network regulating TFC development. In line with this notion, we found 
more than 50% of the genes bound by Blimp1 or E2A were also differentially expressed 
in TFC cells in comparison to non-TFC cells (Fig. S15B, C), suggesting that these two 
transcription factors broadly regulated TFC cell development. Consistent with an 
important function for Tcf1, we also found significant enrichment of genes bound by 
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Tcf1  among the genes differentially expressed in TFC cells (Fig. S15D). In conclusion, 
our data indicate that Bcl6, Blimp1, Tcf1 and E2A (with its regulators Id3 and Id2) form a 
transcriptional circuit that controls the expression of CXCR5 and directs the 
differentiation of TFC cells (Fig. S18). 
Persistence of virus infected cells, in particular TFH cells is one of the major 
obstacles to eliminating HIV infection in individual on antiretroviral therapy (ART). 
Studies on HIV-infected humans and monkeys infected with simian immunodeficiency 
virus (SIV) on ART suggested that insufficient localization of TC cells to B cell follicles is 
at least partially responsible for the high level of infection of TFH cells
8,9,11. Our data 
show that antigen-specific CD8+ T cells can differentiate into a specialized subset of 
cytotoxic effector cells that gain entry into B cell follicles where they can eliminate 
infected TFH cells and B cells. TC entry into the follicles requires up-regulation of Bcl6 
and down-modulation of Blimp1, which not only results in expression of CXCR5, but as 
a trade-off also leads to reduced expression of several cytotoxic effector molecules that 
require high amount of Blimp138,39. Our results therefore demonstrate that elimination of 
virus-infected TFH cells or B cells, or cancerous B cells may not only require boosting 
follicular entry but also cytotoxicity of TFC cells. Understanding how to direct TFC 
differentiation and function may help to design new strategies for eliminating HIV 
persistence in TFH cells in HIV-infected individuals on ART, for controlling the infection 
of B cells with viruses such as by EBV, or for eradicating B cell-derived tumours.  
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METHODS 
Human samples 
Lymph nodes (LN) sections for immunofluorescent stains were obtained by inguinal LN 
resection under local anesthesia, following informed consent with ethical approval at 
University of Minnesota Institutional Review Board. LN cells for flow cytometry were 
obtained by fine needle aspiration from HIV-infected subjects, following informed 
consent with ethical approval at Department of Pathology, Beijing Ditan Hospital, 
Capital Medical University. Subjects’ demographical and clinical characteristics are 
presented in Table S1. Tonsil specimens were obtained following informed consent with 
ethical approval from patients undergoing routine tonsillectomy at the Queen Elizabeth 
Hospital Birmingham via the University of Birmingham Human Biomaterials Resource 
Centre. Unfractionated mononuclear cells (UMs) were isolated. All patients were 
confirmed as EBV-positive by qPCR for viral DNA load in total tonsillar UMs40. 
Mice  
All mice used in this study were male on C57BL/6J background and were maintained in 
specific pathogen free animal facilities in Monash University or the Walter and Eliza Hall 
Institute. For transgenic strains, P14tg/+ TCR transgenic (specific for LCMV gp33-41)
17, 
SMARTAtg/+ TCR transgenic (specific for LCMV gp61-80)
21, OT-Itg/tg TCR transgenic 
(specific for chicken ovalbumin (OVA)257-264), Bcl6
tg/+ transgenic (IμHABcl6, B-cell 
specific transgene)23 were described earlier. The gene-deficient mouse strains, Bcl6Cd4-
Cre (Ref. 41), Prdm1fl/fl-LckCre (Blimp1Lck)38, Id2fl/flLCKCre (Ref. 42), Id3gfp/gfp (GFP knock-
in)28, Tcf7fl/fl-LckCre43, and GFP-reporter strains, Blimp1+/gfp (GFP knock-in)44, Id2+/gfp35, 
Id3+/gfp28 and Il21+/gfp45 were described earlier. Blimp1-bio:Rosa26BirA mice carry a biotin 
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acceptor sequence at the carboxyl terminus of Blimp1, which was biotinylated in vivo by 
coexpression of the Escherichia coli biotin ligase BirA from the Rosa26BirA allele46. 
Animal experiments were approved by the Animal Ethics Committee of the institutes 
responsible for housing the mice. 
Virus infection  
To study the kinetics of CXCR5 expression, cytotoxicity, and follicular entry of CD8+ T 
cells, 6000 purified P14 cells were transferred into congenically marked WT mice. To 
study the function of TFC cells to control TFH infection, 1000 purified P14 and 1000 
SMARTA cells were transferred into OT-I mice. Mice were intravenously (i.v.) injected 
with LCMV (DOCILE) at 2×106 plaque-forming unit (PFU) per mouse one day after 
adoptive transfer of indicated cells. For the study of MuHV-4 infection, MuHV-4 was 
engineered to express enhanced GFP (eGFP) under the intergenic eukaryotic promoter 
EF1α (MuHV4-EF1α-eGFP)22. 2×107 polyclonal CD8 T cells were transferred into OT-1 
mice. One day after adoptive transfer, mice were infected intranasally with 10,000 PFU 
of MuHV4-eGFP. For the infection with influenza virus, 6000 OT-I cells were transferred 
into congenically marked WT mice. Mice were i.v. injected with influenza virus strain x-
31 (H3N2) expressing OVA at 80 TCID50 per mouse one day later. All recipient mice 
were 7-12 weeks old at the time of experiments. Spleens were obtained at indicated 
post-infection time points for analysis. For MuHV-4 infection, mediastinal LNs were 
obtained for analysis. 
Immunization 
6000 OT-I cells were transferred into congenically marked WT mice. 50 μg of OVA was 
emulsified with CFA at 1:1 volume ratio, and 25 μL of the mixture (containing 50 μg of 
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OVA) were injected into the hock of each mouse. Popliteal lymph nodes were obtained 
at day 8 after immunization.  
Cell lines 
C57BL/6-derived MC57 fibrosarcoma cell line was used to titrate virus level in sera and 
spleens. GP+E-86 (GPE86) is a murine embryonic retrovirus packaging cell line used to 
produce retroviruses for transduction. Both cells lines were obtained from American 
Type Culture Collection. Neither cell line is on the list of Cross-Contaminated or 
Misidentified Cell Lines published by International Cell Line Authentication Committee. 
Cultures are free of mycoplasma as tested by PlasmoTest™ (Invivogen). 
Cell preparation 
Cells were prepared by gently mashing spleens or lymph nodes through 70 µm cell 
strainers. Red blood cells were then lysed with the lysis buffer for 10 minutes on ice. 
Single cell suspension (SCS) was prepared by gently pipetting the tissues in complete 
RPMI (cRPMI, consists of 10 mM HEPES, 1X non-essential amino acids solution 
(Gibco), 1 mM sodium pyruvate, 1X Penicillin-Streptomycin-Glutamate solution (PSG, 
Gibco), 55 μM 2-mercaptoethanol and 10% FCS in RPMI media).  
Generation of chimeric mice 
Bone marrow (BM) cells were collected from 7-12 weeks old adult femurs bones by 
flushing out the tissues within the bones, and SCS were prepared by pipetting the 
tissues in cRPMI media. BM cells were cryopreserved in liquid nitrogen until further use. 
Gene-deficient BM cells (CD45.2+) were mixed with WT BM cells (CD45.1+) at 1:1 ratio 
and transferred into Rag1-/- mice, which had been lethally irradiated twice with 4.875 
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gray (Gy) of gamma radiation 4 hours apart. BM cells from WT CD45.2+ BM were also 
mixed with WT CD45.1+ BM and reconstituted in recipient mice as control groups. Mice 
were housed for 6 weeks to allow haematopoietic reconstitution before infection with 
LCMV DOCILE.  
Detection of LCMV DOCILE-infected cells by flow cytometry  
Detection of virus-infected cells by flow cytometry was adapted from a previous study9. 
Briefly, hybridoma of rat anti-LCMV nucleoprotein (clone VL4) was cultured in serum-
free DMEM media. Culture supernatant was collected and VL4 antibody was purified 
using protein A (Invitrogen). Purified antibody was labelled with Alexa Flour 647 (AF647, 
Invitrogen) according to manufacturer’s instruction. To reduce the staining background, 
unconjugated AF647 was removed using ultracentrifugal unit (10 kDa MW cut off, 
Amicon). Infected splenocytes were stained with Fc-receptor blocking antibody (clone 
2.4G2) followed by staining with antibodies against surface markers in FACS buffer for 
1 hour at 4°C. Cells were then intracellular permeabilized using Cytofix/Cytoperm (BD, 
554722) for 30 minutes on ice. AF647-VL4 was incubated with the cells for 30 minutes 
at room temperature (RT). Splenocytes from uninfected mice were used as negative 
control. 
qPCR for quantification of viral and gene expression 
Quantification of DOCILE RNA was performed by a quantitative PCR (qPCR) method 
adapted from a previous study10. Briefly, splenocytes were pooled from eight LCMV 
(DOCILE)-infected mice collected on day 15 p.i. and stained with surface antibodies and 
different subsets of CD4+ T cells were purified by flow cytometry. RNA was isolated 
from sorted cells using the RNAeasy Mini Kit (Qiagen). RNA of LCMV GP and a house 
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keeping gene β-actin was reverse-transcribed using 2 pmol of LCMV GP 
(GCAACTGCTGTGTTCCCGAAAC) and mouse β-actin 
(GAGGTAGTCTGTCAGGTCCC) reverse primers and Superscript III Reversed 
Transcriptase kit (Invitrogen) according to manufacturer’s instruction. Complementary 
DNA were then quantified using the Accupower Q-PCR kit (Bioneer) and the same 
LCMV GP or mouse β-actin reverse primers, with the addition of forward primers for GP 
(CATTCACCTGGACTTTGTCAGACTC) and β-actin (CCAACCGTGAAAAGATGACC). 
For quantification of gene transcripts, Bioneer RT cycler kit were used to synthesis total 
cDNA as per manufacturer’s instruction. cDNA were quantified using qPCR kit as above 
with the following primers: Prdm1 forward 5’ CTTGTGTGGTATTGTCGGGAC 3’ and 
reverse 5’ CACGCTGTACTCTCTCTTGG 3’; Id2 forward 5’ 
ATCCTGTCCTTGCAGGCATC 3’ and reverse 5’ TCTCCTGGTGAAATGGCTGA 3’; Id3 
forward 5’ CATCTCCCGATCCAGACAGC 3’ and reverse 5’ 
GAAGCTCATCCATGCCCTCA 3’; Tcf7 forward 5’ CTATCCCAGGTTCACCCACC 3’, 
and reverse 5’ TTCTCTGCCTTGGGTTCTGC 3’. Relative fold change was calculated 
by 2-(ΔCT experiment - ΔCT control). ΔCT= CTgene of interest – CTβ-actin. 
Virus titration in serum and spleen 
Virus titration was adapted from a previous study47. Briefly, the MC57 murine fibroblast 
cell line was incubated with virus-containing samples to infect MC57 cells for 24 hours 
in complete DMEM (cDMEM, containing 10% FCS and 1X PSG in DMEM media). Cells 
were then washed with DPBS, trypsinized and washed with FACS buffer. Intracellular 
staining with AF647-VL4 was performed on the infected MC57 as described above. 
Infected MC57 were identified as VL4+ cells. A standard curve was generated using a 
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stock of virus with known PFU concentration (as measured by standard plaque forming 
assay). Viral PFU in tested samples were extrapolated using the standard curve. To 
ensure that values fell within the linear range of the standard curve, sera were diluted at 
1:100 and spleens were weighed and homogenized at 100 μg/ml. 
Flow cytometry 
Cells were stained with Fc-receptor blocking antibodies (clone 2.4G2) for 10 minutes on 
ice to block non-specific staining. Primary anti-mouse antibodies were then added and 
incubated for 1 hour at 4°C, followed by 30 minutes of streptavidin or secondary 
antibody staining on ice. Primary anti-human antibodies were incubated for 30 minutes 
at room temperature. Staining for CCR7 was done at 37°C for 20 minutes. For staining 
of intracellular cytokines, whole splenocytes were stimulated with 5 μg/mL of gp33 
peptide in the presence of monensin and brefeldin A (eBioscience, 00-4506 and 00-
4505) for 4 hours at 37°C. Stimulated cells were then subject to the same antibody-
staining protocol as above.  
For intracellular staining, cells were washed twice after surface staining and 
permeabilized using Cytofix/Cytoperm (BD, 554722) for 30 minutes on ice. Antibodies 
specific for intracellular proteins were diluted in Perm/Wash Buffer (BD, 554723) and 
incubated for 30 minutes at RT. For intranuclear staining, cells were permeabilized 
using Transcription Factor Staining Buffer Set (eBioscience, 00-5523-00) for 30 minutes 
on ice. Antibodies specific for intranuclear proteins were diluted in Permeabilization 
Buffer (eBioscience, 00-8333) and incubated for 60 minutes at RT.  
The following anti-mouse antibodies used for staining were purchased from Biolegend 
unless otherwise indicated: Biotin-CXCR5 (clone L138D7), AF488-SLAM (clone TC15-
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12F12.2), PE-Bcl6 (clone K112-91, BD), PE-Perforin (clone eBioOMAK-D, 
eBioscience),  PE-Tim-3 (clone B8.2C12), PECy7-IFNγ (clone XMG1.2, BD), PECy7-
Thy1.1 (BD XX) PE-CD200 (clone OX-90), PECy7-ICOS (clone C398.4A), PECy7-2B4 
(clone m2B4(B6)458.1), APC-Granzyme A (clone GzA-3G8.5, eBioscience), APC-
Ly108 (clone 330-AJ), APC-H-2Db-GP33-tetramer (MBL), APCCy7-CD45.1 (clone A20), 
AF700-CD8 (clone 53-6.7), BV421-PD1 (clone J43, BD), Pacific Blue-Granzyme B 
(clone GB11), BV510-CD44 (clone IM7, BD), BV421-CCR7 (clone 4B12), BV605-IL-7R 
(clone A7R34), BV605-CD4 (clone RM4-5), BV711-CD62L (clone MEL-14), BUV737-
TCRβ (clone H57-59, BD), BUV395-B220 (clone RA3-6B2, BD), Streptavidin-PECy-5.5 
(ThermoFisher Scientific). Antibodies of the same or overlapping fluorophores were 
stained separately. TC and TH cells were gated on CD8
+TCRβ+B220- and 
CD4+TCRβ+B220-, respectively, for FACS analysis. To exclude dead cells, cells were 
stained with 7-AAD. To exclude dead cells from staining protocols that involved 
permeabilization, cells were stained with Zombie Aqua™ Fixable Viability Kit 
(Biolegend) before permeabilization.   
For staining of LN from HIV-infected patients, the following antibodies are used: FITC-
TCRαβ (clone IP26, Biolegend), PECy7-CCR7 (clone G043H7, BD), AF647-CXCR5 
(clone RF8B2, BD), APCCy7-CD45RA (clone HI100, BD), BV510-CD8a (clone RPA-T8, 
BD), BV786-CD19 (clone HIB19, BD). Antibodies of the same or overlapping 
fluorophores were stained separately. TC cells were gated on CD8
+TCRαβ+CD19- for 
FACS analysis. To exclude dead cells, cells were stained with 7-AAD. 
For the staining of EBV specific tonsillar CD8 T cells, according to their HLA class I 
type, tonsillar UMs were exposed for 30mins at 37°C to either HLA-A*0201 tetramers 
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carrying YVLDHLIVV (YVL) or GLCTLVAML (GLC) peptides (derived from EBV 
antigens BRLF1 and BMLF1 respectively), or HLA-B*0801 tetramer carrying 
RAKFKQLL (RAK) peptide (BZLF1), as previously described 48. All tetramers were 
APC-conjugated. Cells were subsequently washed and stained with live/dead fixable 
violet cell stain kit (Invitrogen) for 20 mins at RT. Following a further wash, cells were 
stained with the following antibodies for 30 minutes at RT: CD4 ECD (clone 
SFCI12T4D11, Beckman Coulter), CD8 Brilliant Violet 510 (clone SK1, Biolegend), 
CD14 Pacific Blue (clone HCD14, Biolegend), CD19 Pacific Blue (clone HIB19, 
Biolegend), CXCR5 PE-Cy7 (clone J252D4, Biolegend), CD45RA Alexa Fluor 700 
(clone HI100, Biolegend), CCR7 FITC (clone 150503, R&D Systems).  
All samples were subsequently analyzed using BD LSR II flow cytometer. Validation 
profile and citation for each antibody can be found on 1DegreeBio website. 
Immunofluorescence  
Immunofluorescence analysis was performed either alone or after RNAscope in situ 
hybridization as previously described11,27,49. For mouse spleen tissues, middle section of 
spleens were cut and submerged in optimal cutting temperature (OCT) compound and 
stored at -80°C. Human LNs were processed in similar fashion. OCT block were then 
sectioned at 6-7µm thickness and fixed with acetone for 10 minutes at -20°C. Sections 
were blocked with Fc-receptor blocking antibody (clone 2.4G2) followed by staining with 
primary antibodies and secondary antibodies. All steps were performed at RT for 60 
minutes in the dark. Slides were washed and incubated with 0.1% Sudan Black B in 
70% ethanol (Cat. No.4410; ENG Scientific) followed by TBS for 30 minutes at room 
temperature to quench autofluorescence. Sections were counterstained with DAPI and 
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mounted using Fluoromount GTM (ProSciTech) or Prolong® Gold (Invitrogen). Mouse 
sections were visualized using an Olympus Provis AX70 Widefield fluorescence 
microscope. Human LN sections were visualized using Olympus FV10i confocal 
microscope using a 60x phase contrast oil-immersion objective (NA 1.35) imaging. 
Quantification of Tc was performed by visually counting cells per area of section. 
Follicular/Non-Follicular ratio was calculated by dividing number of follicular by non-
follicular P14.  
The following anti-mouse antibodies were used for immunofluorescence: Biotin-CD3 
(clone 145-2C11, Biolegend), Biotin-CD4 (clone H129.19, BD), AF647-B220 (clone 
RA3-6B2, Biolegend), AF647-CD45.1 (clone A20, Biolegend), AF488-CD8 (clone 53-
6.7, Biolegend) and AF555-streptavidin (ThermoFisher Scientific). Following anti-human 
antibodies were used: rabbit monoclonal anti-CD8 (clone SP16, Thermofisher) and 
mouse monoclonal anti-CD20 (clone L26, Dako) with AF488 or AF594-donkey anti-
rabbit, and AF488 or AF647-donkey anti-mouse (Invitrogen). Validation profile and 
citation for each antibody can be found on 1DegreeBio website. 
Retroviral vector-mediated gene overexpression  
GFP bicistronic retroviral vector containing Bcl6 has been described25. mCherry 
bicistronic retroviral vector containing Id3 was generated by cloning Id3 into the vector. 
Thy1.1 reporter constructs (Fig S15B) were kindly provided by Lilin Ye29. Cloning of 
cassettes were performed as previously described29. Retroviruses were then generated 
by transfecting the plasmids into a retrovirus-packaging cell line GPE86. GFP or 
mCherry positive GPE86 were sorted to isolate stably transfected cells. Stably 
transfected GPE86 were then cultured in cDMEM for 48 hours and retrovirus in the 
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culture supernatant were collected for the transduction of primary CD8+ T cells. To 
prepare primary CD8+ T cells for transduction, naïve CD8+ T cells were purified from 
P14 mice and stimulated with plate-bound anti-CD3 and anti-CD28 for 48 hours. For the 
transduction, cells were spinoculated at 800 g for 1 hour at 32°C. Cells were rested in 
fresh cRPMI media containing 20 ng/mL of rmIL7. After 48 hours, GFP+ or mCherry+ 
P14 were sorted and 6000 sorted cells were transferred into congenically marked WT 
mouse. 24 hours later, mice were infected with LCMV (DOCILE). For the study of Bcl6 
overexpression on transcriptional regulation of other genes, cells were rested in 10 
ng/mL of IL-2 and 100 ng/mL of IL-12 for 48 hours, GFP+ cells were then sorted and 
subjected to Q-PCR analysis as described above. 
Ex vivo cytotoxic assay 
The ex vivo cytotoxic assay was adapted from a previous study50. Briefly, CD44-
CD62L+CXCR5- (Naïve) P14 cells were sorted from P14 mice and transferred into 
congenically marked WT host, followed by infection with Docile. 8 days after infection, 
splenocytes were isolated and sorted for CD44+CD62L-CXCR5- (CXCR5- non-TFC) and 
CD44+CD62L-CXCR5+ (CXCR5+ TFC) P14 cells. These cells were used as effector cells 
(E). To prepare target cells, splenocytes were isolated from uninfected WT mice and 
stained with 20 μM or 1 μM of cell trace violet (CTV) dye (Invitrogen). 20 μM-stained 
(CTVhi) splenocytes were incubated with gp33 peptide (KAVYNFATM) at 10 μg/mL for 1 
hour at 37°C in cRPMI media. 1 μM-stained splenocytes (CTVlo) were incubated with 
cRPMI media alone. Cells were then washed extensively, counted, mixed at 1:1 ratio 
and used as target cells (T). To prepare TFH and non-TFH target cells, SMARTA cells 
were injected into congenic WT mice and infected with DOCILE. D8 p.i., in vivo 
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differentiated TFH and non-TFH SMARTA cells were sorted and stain with CTV as 
above. Effector cells and target cells were then mixed at 4:1 E:T ratio in U-bottom 96-
well and cultured for 10 hours in cRPMI at 37°C. Cells were then stained with 7-AAD to 
exclude dead cells and analyzed with flow cytometry. % specific cytotoxicity was 
calculated as follows:  
Effector cytotoxicity (A) = (%CTVhi/%CTVlo) 
Target only cytotoxicity (B) = (%CTVhi/%CTVlo) 
% specific cytotoxicity = (1-A/B)×100 
For ex vivo cytotoxicity of Bcl6-overexpressed P14 cells, transduced cells were re-
stimulated with plate-bound anti-CD3/CD28 for 24 hours. GFP+ cells were sorted and 
used as effector cells in the ex vivo cytotoxicity assay as described above.  
RNA sequencing  
CD44-CD62L+CXCR5- naïve CD8+ T cells were purified from P14 mice and transferred 
into congenically marked WT mice. RNA was also extracted from purified naïve P14 
cells. 24 hours after adoptive transfer, mice were then infected with LCMV (DOCILE). 8 
days p.i., splenocytes were collected and sorted for CD44+CXCR5- (CXCR5- non-TFC) 
and CD44+CXCR5+ (CXCR5+ TFC) P14 cells, followed by RNA extraction using the 
RNAeasy Micro Kit (Qiagen). RNA integrity was analyzed using Agilent RNA 6000 Nano 
Kit (Agilent). PolyA-enrichment was used for library preparation and 50 bp one-end 
sequencing was performed by Monash Health Translation Precinct Medical Genomics 
Facility. 
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For the transcriptional profiling of Blimp1-deficient CD8 T cells, we generated mixed 
bone marrow chimeric mice of Blimp1LCK as described above. These mice were rested 
for 6-9 weeks and first inoculated i.p. with 107 PFU of influenza virus A/PR/8/34, 
followed by secondary infection with the x31 4-6 weeks later. 9 days after x31 infection, 
mediastinal LN were obtained, and antigen-specific CD8+ T cells were sorted using 
MHC class I (H-2Db) tetramers complexed with influenza NP366-374 (NP366) peptide. RNA 
isolation and sequencing were then performed as above. 
Bio-ChIP sequencing 
Blimp1Bio/Bio and Tcf3Bio/Bio mice carry a biotin acceptor sequence at the carboxyl 
terminus of Blimp1 and E2A (Tcf3), which can be biotinylated in vivo by coexpression of 
the Escherichia coli biotin ligase BirA from the Rosa26BirA allele. Blimp1 Bio-ChIP-seq 
was performed with splenic CD8+ T cells from Blimp1Bio/Bio Rosa26BirA/BirA mice that were 
stimulated first with anti-CD3, anti-CD28 and IL-2 (100 U/ml) for 3 days and then with 
IL-2 and IL-12 (5 ng/ml) for another 2 days. Chromatin from ~3 x 108 CD8+ T cells was 
prepared using a lysis buffer containing 0.25% SDS prior to chromatin precipitation by 
streptavidin pulldown (Bio-ChIP), as described46. The precipitated genomic DNA was 
quantified by real-time PCR. E2A Bio-ChIP-seq was performed with total thymocytes 
from Tcf3Bio/Bio Rosa26BirA/BirA mice. The precipitated genomic DNA was amplified with 
the KAPA Real Time Amplification kit (KAPA Biosystems). Cluster generation and 
sequencing was carried out using the Illumina HiSeq 2000 system with a read length of 
50 nucleotides according to the manufacturer’s guidelines. 
To analyze ChIP-seq data, Bowtie2.2.8 has been used for alignment with mouse 
mm9 as reference genome, MACS2.1.0 for peak calling with p value 10e-10 as cutoff. 
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The peak table with the peak starting and ending location was mapped to genes with 
the following strategies: Peaks were assigned to genes in a stepwise manner by 
prioritizing genes containing peaks in their promoter and/or gene body. For this, peaks 
with -2.5 kb to TSS and +2.5 kb to TES were first assigned to the corresponding gene. 
Other peaks within 50kb to gene body were assigned to the nearest gene for long 
distance regulation. R functions Venn in g-plots package and barcode plots in limma 
package were used to generate the figures. Bcl6 ChIP-seq (GSM1857225)37, E2A 
ChIP-seq (to be deposited to the GEO repository) and Tcf1 ChIP-seq (GSM1889262)51 
were obtained from published data. 
Bioinformatics analysis of RNA sequencing and ChIP-seq data 
To analyze RNA sequencing data, RPKM (Read per kilobase per million) were obtained 
from raw dataset and log2 transformed after replacing zero by the minimum value in the 
dataset. The log2 RPKM data were quantile normalized. The R statistical software 
(version 3.1.2) was used to calculate differentially expressed genes between naïve, 
CXCR5+ TFC, and CXCR5
- non-TFC cells. Genes satisfying the following criteria were 
chosen for analysis: first, the average count is more than 100 in at least one sample 
group and second, the global false discovery rate (FDR) is controlled at 0.05 with a 
minimum fold-change of 2. This generated a “TFC versus non-TFC signature gene set”. 
The same method was used to generate the “Blimp1 KO versus Blimp1 WT gene set”. 
RNA sequencing results can be accessed under GSE68056. The same methods were 
used to generate TFH vs non-TFH cells signature gene set (GSE16697)
25, Id2 KO vs WT 
gene set (GSE44140)35, Id3 KO vs WT gene set (GSE23568)34 from previously 
published data. 
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For the enrichment analysis, rotation gene set test (ROAST) of the signature gene set 
between each dataset was compared, providing the directional p-values and the 
percentage of the commonly regulated genes in the barcode plots.    
Statistical analysis 
Preliminary experiments were performed using 3-5 mice to determine the expected 
means and sample distributions of the control and experimental groups. The means and 
sample distributions were then used to calculate the sample size required to test the 
hypothesis in subsequent experiments using MedCalc (exact numbers of samples were 
indicated in figure legend). As normality of the sample distributions cannot be tested 
with small sample sizes (n ≤ 5), non-parametric two-sided Mann-Whitney’s U-tests were 
performed for comparison between two groups without assumption of normal 
distribution. One-way ANOVA was used to calculate univariate data set with more than 
two groups. Two-way ANOVA was used to calculate multivariate data set. Wilcoxon 
matched-pairs rank test was to calculate paired samples between two groups. 
Repeated-measure (RM) two-way ANOVA was used to calculate paired multivariate 
samples. Animals were of matched sex and age, no randomisation were performed for 
the grouping of animals. Blinding was not performed due to the objective measurement 
of the experimental data. All statistical analysis were performed using Prism GraphPad. 
  
Page 27 
 
REFERENCES 
1 Mueller, S. N., Gebhardt, T., Carbone, F. R. & Heath, W. R. Memory T cell 
subsets, migration patterns, and tissue residence. Annual review of immunology 
31, 137-161, doi:10.1146/annurev-immunol-032712-095954 (2013). 
2 Vinuesa, C. G., Linterman, M. A., Yu, D. & MacLennan, I. C. Follicular Helper T 
Cells. Annual review of immunology 34, 335-368, doi:10.1146/annurev-immunol-
041015-055605 (2016). 
3 Barton, E., Mandal, P. & Speck, S. H. Pathogenesis and host control of 
gammaherpesviruses: lessons from the mouse. Annual review of immunology 
29, 351-397, doi:10.1146/annurev-immunol-072710-081639 (2011). 
4 Lindqvist, M. et al. Expansion of HIV-specific T follicular helper cells in chronic 
HIV infection. The Journal of clinical investigation 122, 3271-3280, 
doi:10.1172/jci64314 (2012). 
5 Petrovas, C. et al. CD4 T follicular helper cell dynamics during SIV infection. The 
Journal of clinical investigation 122, 3281-3294, doi:10.1172/jci63039 (2012). 
6 Perreau, M. et al. Follicular helper T cells serve as the major CD4 T cell 
compartment for HIV-1 infection, replication, and production. The Journal of 
experimental medicine 210, 143-156, doi:10.1084/jem.20121932 (2013). 
7 Pissani, F. & Streeck, H. Emerging concepts on T follicular helper cell dynamics 
in HIV infection. Trends in immunology 35, 278-286, doi:10.1016/j.it.2014.02.010 
(2014). 
8 Banga, R. et al. PD-1 and follicular helper T cells are responsible for persistent 
HIV-1 transcription in treated aviremic individuals. Nature medicine, 
doi:10.1038/nm.4113 (2016). 
9 Hong, J. J., Amancha, P. K., Rogers, K., Ansari, A. A. & Villinger, F. Spatial 
alterations between CD4(+) T follicular helper, B, and CD8(+) T cells during 
simian immunodeficiency virus infection: T/B cell homeostasis, activation, and 
potential mechanism for viral escape. Journal of immunology 188, 3247-3256, 
doi:10.4049/jimmunol.1103138 (2012). 
10 Vinuesa, C. G. HIV and T follicular helper cells: a dangerous relationship. The 
Journal of clinical investigation 122, 3059-3062, doi:10.1172/JCI65175 (2012). 
11 Fukazawa, Y. et al. B cell follicle sanctuary permits persistent productive simian 
immunodeficiency virus infection in elite controllers. Nature medicine 21, 132-
139, doi:10.1038/nm.3781 (2015). 
12 Kaech, S. M. & Cui, W. Transcriptional control of effector and memory CD8+ T 
cell differentiation. Nature reviews. Immunology 12, 749-761, 
doi:10.1038/nri3307 (2012). 
13 Chang, J. T., Wherry, E. J. & Goldrath, A. W. Molecular regulation of effector and 
memory T cell differentiation. Nature immunology 15, 1104-1115, 
doi:10.1038/ni.3031 (2014). 
14 Quigley, M. F., Gonzalez, V. D., Granath, A., Andersson, J. & Sandberg, J. K. 
CXCR5+ CCR7- CD8 T cells are early effector memory cells that infiltrate tonsil B 
cell follicles. European journal of immunology 37, 3352-3362, 
doi:10.1002/eji.200636746 (2007). 
15 Vinuesa, C. G. & Cyster, J. G. How T cells earn the follicular rite of passage. 
Immunity 35, 671-680, doi:10.1016/j.immuni.2011.11.001 (2011). 
Page 28 
 
16 Zhou, X., Ramachandran, S., Mann, M. & Popkin, D. L. Role of lymphocytic 
choriomeningitis virus (LCMV) in understanding viral immunology: past, present 
and future. Viruses 4, 2650-2669, doi:10.3390/v4112650 (2012). 
17 Kyburz, D. et al. T cell immunity after a viral infection versus T cell tolerance 
induced by soluble viral peptides. European journal of immunology 23, 1956-
1962, doi:10.1002/eji.1830230834 (1993). 
18 Hogquist, K. A. et al. T cell receptor antagonist peptides induce positive 
selection. Cell 76, 17-27 (1994). 
19 Homann, D., McGavern, D. B. & Oldstone, M. B. Visualizing the viral burden: 
phenotypic and functional alterations of T cells and APCs during persistent 
infection. Journal of immunology 172, 6239-6250 (2004). 
20 Baca Jones, C. et al. Direct infection of dendritic cells during chronic viral 
infection suppresses antiviral T cell proliferation and induces IL-10 expression in 
CD4 T cells. PloS one 9, e90855, doi:10.1371/journal.pone.0090855 (2014). 
21 Oxenius, A., Bachmann, M. F., Zinkernagel, R. M. & Hengartner, H. Virus-
specific MHC-class II-restricted TCR-transgenic mice: effects on humoral and 
cellular immune responses after viral infection. European journal of immunology 
28, 390-400 (1998). 
22 Gaspar, M. et al. Murid herpesvirus-4 exploits dendritic cells to infect B cells. 
PLoS Pathog 7, e1002346, doi:10.1371/journal.ppat.1002346 (2011). 
23 Afshar-Sterle, S. et al. Fas ligand-mediated immune surveillance by T cells is 
essential for the control of spontaneous B cell lymphomas. Nature medicine 20, 
283-290, doi:10.1038/nm.3442 (2014). 
24 Kim, H. J., Verbinnen, B., Tang, X., Lu, L. & Cantor, H. Inhibition of follicular T-
helper cells by CD8(+) regulatory T cells is essential for self tolerance. Nature 
467, 328-332, doi:10.1038/nature09370 (2010). 
25 Johnston, R. J. et al. Bcl6 and Blimp-1 are reciprocal and antagonistic regulators 
of T follicular helper cell differentiation. Science 325, 1006-1010, 
doi:10.1126/science.1175870 (2009). 
26 Nurieva, R. I. et al. Bcl6 mediates the development of T follicular helper cells. 
Science 325, 1001-1005, doi:10.1126/science.1176676 (2009). 
27 Yu, D. et al. The transcriptional repressor Bcl-6 directs T follicular helper cell 
lineage commitment. Immunity 31, 457-468, doi:10.1016/j.immuni.2009.07.002 
(2009). 
28 Miyazaki, M. et al. The opposing roles of the transcription factor E2A and its 
antagonist Id3 that orchestrate and enforce the naive fate of T cells. Nature 
immunology 12, 992-1001, doi:10.1038/ni.2086 (2011). 
29 Choi, Y. S. et al. LEF-1 and TCF-1 orchestrate T(FH) differentiation by regulating 
differentiation circuits upstream of the transcriptional repressor Bcl6. Nature 
immunology 16, 980-990, doi:10.1038/ni.3226 (2015). 
30 Wu, T. et al. TCF1 Is Required for the T Follicular Helper Cell Response to Viral 
Infection. Cell reports 12, 2099-2110, doi:10.1016/j.celrep.2015.08.049 (2015). 
31 Xu, L. et al. The transcription factor TCF-1 initiates the differentiation of T(FH) 
cells during acute viral infection. Nature immunology 16, 991-999, 
doi:10.1038/ni.3229 (2015). 
Page 29 
 
32 Shaw, A. L. et al. Id2 reinforces TH1 differentiation and inhibits E2A to repress 
TFH differentiation. Nature immunology (2016). 
33 Xin, A. e. a. A combinatorial threshold model for effector differentiation of CD8+ T 
cells mediated by Blimp-1 and T-bet. Nature immunology In press (2016). 
34 Ji, Y. et al. Repression of the DNA-binding inhibitor Id3 by Blimp-1 limits the 
formation of memory CD8+ T cells. Nature immunology 12, 1230-1237, 
doi:10.1038/ni.2153 (2011). 
35 Masson, F. et al. Id2-mediated inhibition of E2A represses memory CD8+ T cell 
differentiation. Journal of immunology 190, 4585-4594, 
doi:10.4049/jimmunol.1300099 (2013). 
36 Hatzi, K. et al. BCL6 orchestrates Tfh cell differentiation via multiple distinct 
mechanisms. J Exp Med 212, 539-553, doi:10.1084/jem.20141380 (2015). 
37 Liu, X. et al. Genome-wide Analysis Identifies Bcl6-Controlled Regulatory 
Networks during T Follicular Helper Cell Differentiation. Cell reports 14, 1735-
1747, doi:10.1016/j.celrep.2016.01.038 (2016). 
38 Kallies, A., Xin, A., Belz, G. T. & Nutt, S. L. Blimp-1 transcription factor is 
required for the differentiation of effector CD8(+) T cells and memory responses. 
Immunity 31, 283-295, doi:10.1016/j.immuni.2009.06.021 (2009). 
39 Rutishauser, R. L. et al. Transcriptional repressor Blimp-1 promotes CD8(+) T 
cell terminal differentiation and represses the acquisition of central memory T cell 
properties. Immunity 31, 296-308, doi:10.1016/j.immuni.2009.05.014 (2009). 
40 Junying, J. et al. Absence of Epstein-Barr virus DNA in the tumor cells of 
European hepatocellular carcinoma. Virology 306, 236-243 (2003). 
41 Hollister, K. et al. Insights into the role of Bcl6 in follicular Th cells using a new 
conditional mutant mouse model. Journal of immunology 191, 3705-3711, 
doi:10.4049/jimmunol.1300378 (2013). 
42 Jackson, J. T. et al. Id2 expression delineates differential checkpoints in the 
genetic program of CD8alpha+ and CD103+ dendritic cell lineages. EMBO J 30, 
2690-2704, doi:10.1038/emboj.2011.163 (2011). 
43 Steinke, F. C. et al. TCF-1 and LEF-1 act upstream of Th-POK to promote the 
CD4(+) T cell fate and interact with Runx3 to silence Cd4 in CD8(+) T cells. 
Nature immunology 15, 646-656, doi:10.1038/ni.2897 (2014). 
44 Kallies, A. et al. Plasma cell ontogeny defined by quantitative changes in blimp-1 
expression. J Exp Med 200, 967-977, doi:10.1084/jem.20040973 (2004). 
45 Luthje, K. et al. The development and fate of follicular helper T cells defined by 
an IL-21 reporter mouse. Nature immunology 13, 491-498, doi:10.1038/ni.2261 
(2012). 
46 Minnich, M. et al. Multifunctional role of the transcription factor Blimp-1 in 
coordinating plasma cell differentiation. Nature immunology 17, 331-343, 
doi:10.1038/ni.3349 (2016). 
47 Korns Johnson, D. & Homann, D. Accelerated and improved quantification of 
lymphocytic choriomeningitis virus (LCMV) titers by flow cytometry. PloS one 7, 
e37337, doi:10.1371/journal.pone.0037337 (2012). 
48 Hislop, A. D., Annels, N. E., Gudgeon, N. H., Leese, A. M. & Rickinson, A. B. 
Epitope-specific evolution of human CD8(+) T cell responses from primary to 
Page 30 
 
persistent phases of Epstein-Barr virus infection. J Exp Med 195, 893-905 
(2002). 
49 Deleage, C. et al. Defining HIV and SIV Reservoirs in Lymphoid Tissues. Pathog 
and Immun 1, 39, doi:10.20411/pai.v1i1.100 (2016). 
50 Jedema, I., van der Werff, N. M., Barge, R. M., Willemze, R. & Falkenburg, J. H. 
New CFSE-based assay to determine susceptibility to lysis by cytotoxic T cells of 
leukemic precursor cells within a heterogeneous target cell population. Blood 
103, 2677-2682, doi:10.1182/blood-2003-06-2070 (2004). 
51 Xing, S. et al. Tcf1 and Lef1 transcription factors establish CD8(+) T cell identity 
through intrinsic HDAC activity. Nature immunology 17, 695-703, 
doi:10.1038/ni.3456 (2016). 
 
  
Page 31 
 
ACKNOWLEDGEMENTS 
The authors acknowledge the facilities, scientific and technical assistance of Flowcore, 
Monash Micro Imaging, and Monash Bioinformatics Platform (Stuart Archer and Kirill 
Tsyganov) at Monash University, and University of Birmingham’s Human Biomaterials 
Resource Centre, which has been supported through Birmingham Science City - 
Experimental Medicine Network of Excellence project. We thank Carola Vinuesa 
(Australian National University) and Stephen Nutt (Walter and Eliza Hall Institute of 
Medical Research, WEHI) for mice, Renee Gloury and Liana Mackiewicz (WEHI) for 
technical support, Chen Dong (Tsinghua University) and Hai-Hui Xue (University of 
Iowa) for gene lists of Bcl6 and Tcf1 bound genes, respectively. This work was 
supported by grants and fellowships from the National Health and Medical Research 
Council (NHMRC) of Australia (PhD Scholarship to Y.A.L., CDF Fellowship 
GNT1085509 to D.Y., Grant GNT1085151 to A.K., Practitioner Fellowship to S.R.L.), 
Monash University (D.Y.), amfAR Research Consortium on HIV Eradication (ARCHE) 
(109327-59-RGRL, D.Y., S.R.L. and A.L.L.), The International AIDS Society “The 
Creative and Novel Ideas in HIV Research” (CNIHR) Program (D.Y.), Australian Centre 
for HIV and Hepatitis Virology Research (ACH2) grant (2015-69, D.Y.), The Priority 
Research Program of Shandong Academy of Sciences (D.Y.), Shandong Province 
Taishan Scholar Program (D.Y.), Shandong Academy the Sylvia and Charles Viertel 
Foundation (A.K.), the Delaney AIDS Research Enterprise (DARE) to find a cure, Martin 
Delaney Collaboratories, National Institute for Allergy and Infectious Diseases, National 
Institutes of Health (U19 AI096109, S.R.L., T.W.S. and J.D.E.), Bloodwise, UK (15021, 
H.M.L. and B.J.M.), and the Victorian State Government Operational Infrastructure 
Page 32 
 
Support and Australian Government NHMRC Independent Research Institute 
Infrastructure Support scheme. This project has been funded in part with federal funds 
from the national cancer institute, national institutes of health, under contract no. 
HHSN261200800001E. The content of this publication does not necessarily reflect the 
views or policies of the department of health and human services, nor does mention of 
trade names, commercial products, or organizations imply endorsement by the U.S. 
Government. 
 
AUHTOR CONTRIBUTIONS 
Y.A.L. planned and performed most experiments with the support from Y.C. and H.S.O.; 
Y.C. and A.A. performed experiments related to retrovirus-mediated gene 
overexpression; D.W. and J.X. performed bioinformatics analysis; K.M. performed 
experiments to generate chimeric mice; C.D, J.G.C., G.J.B., T.W.S. and J.D.E. 
performed immunofluorescent staining and quantification of HIV samples; M.M., M.B. 
and A.K. did or analyzed the ChIP sequencing experiments; B.J.M., H.M.L. and U.P. 
performed analysis of EBV samples; Y.W. Z.H., L.S., P.W., and Y.T. performed flow 
cytometry on HIV samples; K.A.F., I.C. and S.R.M. performed the experiment of 
influenza infection; J.G.T., C.C.A. and M.P. provided support for experiments of LCMV 
and relevant models; H.K.L. provided support for experiment to quantify viral RNA; 
A.L.D. provided Bcl6fl/fl mice. G.T.B. provided support on MuHV-4 model; A.L.L. and 
S.R.L. contributed to the scientific planning; D.Y. and A.K. oversaw and designed the 
study; Y.A.L. and D.Y. analyzed data; D.Y., Y.A.L. and A.K. wrote the manuscript.  
  
Page 33 
 
 
LEGENDS 
Figure 1: CXCR5 mediates the follicular entry of TC cells. (A) Immunofluorescent 
(IF) staining of B cells (anti-CD20, green), CD8+ T cells (anti-CD8, red), and nuclei 
(DAPI, blue) of lymph node (LN) sections from HIV-uninfected (HIV-) or HIV-infected 
(HIV+) individuals. The number of CD8+ T cells in B cell follicle (F) and T cell zone (T) 
were calculated from 7 uninfected and 15 HIV-infected individuals, respectively. (B) IF 
staining of HIV-RNA (red), CD8+ T cells (green) and B cells (blue) of LN section from an 
HIV-infected individual. Higher magnification of the B cell follicle is shown in yellow box 
insets, scale bar = 100µm (A, B). (C) Flow cytometry (FACS) analysis of CXCR5 
expression on naïve (CCR7+CD45RA+) or effector (CCR7-CD45RA-) TC in LN from HIV-
infected individuals. Each symbol represents naïve or effector populations from four 
individuals. (D-F) Congenically marked (CD45.1+) P14 cells were adoptively transferred 
into wildtype (WT) (CD45.2+) mice, which were then infected with LCMV (DOCILE). (D) 
IF staining of B cells (anti-B220, red) and P14 cells (anti-CD45.1, green) in splenic 
sections collected at indicated time points post-infection (p.i.). (E) FACS analysis of 
CXCR5 expression on P14 cells or on endogenous gp33-H-2D
b tetramer+ TC cells (from 
WT mice without P14 cells) at day 8 (D8) p.i. (F) CXCR5 expression on P14 cells at 
indicated time points p.i. (G) CD45.2+ WT mice that had received Cxcr5+/+ or Cxcr5-/- 
P14 cells were infected with LCMV (DOCILE). IF staining of splenic sections show the 
localization of P14 cells at day 15 p.i. The number of P14 cells in B cell follicle and T cell 
zone were calculated from 8 independent sections of 4 mice for each group. (H) FACS 
analysis of CXCR5 expression on polyclonal TC cells in the mediastinal LN of uninfected 
or MuHV4-infected mice (D8 p.i.). (I) FACS analysis of tonsil cells from healthy EBV-
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carriers shows the CXCR5 expression on naïve or tetramer+ (Tet+) TC cells. Each 
symbol represents naïve or tetramer+ TC from two healthy carriers with HLA-A*0201 
(YVL and GLC peptides) and one with HLA-B*0801 (RAK peptide) haplotypes. Data are 
representative of two (D-F, H) or three (G) independent experiments. Each symbol 
represents the value of an independent section (A, G) or one mouse (F, H); bars 
represent means. *P < 0.05, **P < 0.01, as calculated by Wilcoxon matched-pairs signed 
rank test (C, I), one-way ANOVA (F, H) or two-way ANOVA (A, G) followed by Sidak’s 
multiple comparison test. 
 
Figure 2: TFC cells specifically control infection in B cell follicles. (A-C) Mice were 
infected with LCMV (DOCILE). IF staining of a spleen section representative of 5 mice 
showing the infection of TH cells (B220, green, CD4, red and LCMV, blue) in B cell 
follicle (upper right) and T cell zone (lower right) at D15 p.i. (A). Infection in TH subsets 
(gated as in B) was measured by intracellular staining with anti-LCMV nucleoprotein 
(NP) antibody (VL4) at indicated time points (C). (D-E) OT-I mice that had received P14 
and SMARTA cells were infected with LCMV (DOCILE). Gating of TFH and non-TFH 
subsets (D) was shown together with infection of TFH (E, top) and non-TFH (E, bottom) 
subsets from SMARTA cells. Graphs show the infection level of each subset (E, right 
panel). (F) OT-I mice that had received polyclonal Tc were infected with MuHV4-EF1α-
eGFP. Infected B cells were measured by GFP expression on B220+ cells by FACS at 
D9 p.i.. Each symbol represents one mouse; bars represent means. Data are 
representative of two independent experiments. *P < 0.05, **P < 0.01, as calculated by 
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Mann-Whitney’s U-test (F), one-way ANOVA (C) or two-way ANOVA  (E) followed by 
Sidak’s multiple comparison tests. 
 
Figure 3: CXCR5+ TFC cells have a distinct transcriptional profile and phenotype. 
Congenically marked (CD45.1+) P14 cells were adoptively transferred into WT 
(CD45.2+) mice, which were then infected with LCMV (DOCILE). (A) At D8 p.i., CXCR5+ 
TFC and CXCR5
- non-TFC P14 cells sorted from three infected mice were subjected to 
RNA-Seq. Depicted in black are the 650 and 551 genes found to be significantly (P 
value < 0.05, fold changes ≥ 2) up-regulated or down-regulated, respectively, in TFC 
compared to non-TFC cells. Selected differentially expressed genes were highlighted in 
red (up-regulated) or blue (down-regulated). (B-E) FACS histograms show the 
expression of indicated proteins in naïve (grey), CXCR5+ TFC (red) and CXCR5
- non-TFC 
(blue) cells as gated in (B) at D8 p.i. GMFI: geometric mean fluorescence intensity. (F) 
Ex vivo killing of LCMV gp33-41 peptide-pulsed splenocytes by naïve, CXCR5
+ TFC or 
CXCR5- non-TFC P14 cells purified at D8 p.i. Each symbol represents one mouse; bars 
represent means. Data are representative of two (B-E) to three (F) independent 
experiments. **P < 0.01, as calculated by one-way ANOVA followed by Sidak’s multiple 
comparison test. 
 
Figure 4: Transcriptional regulation of TFC differentiation. (A, B) Expression of 
transcriptional regulators Bcl6, Tcf1, Id3, Blimp1 and Id2 as determined by intracellular 
staining (Bcl6 and Tcf1) or GFP reporter (Id3, Blimp1 and Id2). FACS histograms show 
the expression of indicated genes in naïve CD8 (grey), CXCR5+ TFC (red) and CXCR5
- 
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non-TFC (blue) cells at D8 p.i. (C-D) Congenically marked P14 cells were transduced 
with a retroviral vector (RV) encoding GFP or Bcl6 (along with GFP), and transferred 
into recipient mice. At D8 p.i., the expression of CXCR5 on transduced cells was 
measured by FACS (C), and follicular positioning was quantified by IF staining (D). (E) 
Analysis of CXCR5 expression on control (Bcl6fl/fl) or Bcl6-deficient (Bcl6fl/flCd4cre) P14 
cells. (F-I) CXCR5 expression on antigen-specific CD8 T cells in LCMV (DOCILE)-
infected chimeric mice generated from a 1:1 mixture of congenically marked control 
(Prdm1fl/fl) or Blimp1-deficient (Prdm1fl/flLckcre) (F), control (Tcf7fl/fl) or Tcf7-deficient 
(Tcf7fl/flLckcre) (G), control (Id2fl/fl) or Id2-deficient (Id2fl/flLckcre) (H), and control (Id3+/+) or 
Id3-deficient (Id3gfp/gfp) (I) bone marrow (BM) cells on D15 p.i.. Graphs show the paired 
analyses of CXCR5+ gp33-H-2D
b tetramer+ TC cells derived from WT or gene deficient 
donor BM cells. (J) P14 cells were transduced with RV or Id3-RV. At D8 p.i., the 
expression of CXCR5 on transduced cells was measured by FACS. (K) Binding of 
Blimp1 and E2A at the Cxcr5 locus, as shown by ChIP-seq analysis of CD8+ effector T 
cells and total thymocytes, respectively. Binding regions, which were identified by 
MACS peak calling, are indicated by black rectangles below the horizontal axis. RPM: 
Reads per million. (L) WT or mutated Blimp1 binding sites at 5’ upstream were cloned 
together with Cxcr5-promoter into retroviral Thy1.1-reporter constructs, followed by 
transduction into P14 cells. Transduced P14 cells were then injected into congenically 
marked recipient mice that were subsequently infected with LCMV (DOCILE). At D8 p.i., 
expression of Thy1.1 (% × GMFI of Thy1.1+) was measured on TFC and non-TFC P14 
cells. (M) Blimp1 and E2A binding sites at 1st intron were sequentially mutated and 
cloned into the same vector (L) and subsequently transduced into P14 cells. Thy1.1 
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expression was measured as in (L). Each symbol represents one mouse; bars 
represent means; lines represent paired samples. Data are representative of at least 
two independent experiments. *P < 0.05, **P < 0.01, as calculated by Mann-Whitney’s 
U-test (C, D, E, J, L), one-way ANOVA (M), two-way ANOVA (D) and RM two-way 
ANOVA (F, G, H, I) followed by Sidak’s multiple comparison tests.  
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Figure S1: Follicular entry of polyclonal TC cells in LCMV infection. 
Staining of anti-CD3 (red), anti-CD8 (green) and anti-B220 (blue) of splenic sections from 
uninfected mice or mice at day 8 post-infection (p.i.). Higher magnification of B cell follicles from 
mice at day 8 p.i. was shown (lower panel). CD8+ T cells (yellow) are identified by co-staining with 
anti-CD3 and anti-CD8. Data are representative of 2 independent experiments. 
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Figure S2: The expression of CXCR5 and CCR7 on CD8+ T cells. 
(A) CD45.1+ P14 cells were adoptively transferred into congenically marked (CD45.2) wildtype 
mice, which were then infected with LCMV (DOCILE). Flow cytometric analysis of CCR7 
expression on P14 cells or endogenous activated CD44+ TC cells at day 8 p.i.  
(B) CD45.1+ CXCR5+/+ or CXCR5-/- P14 cells were adoptively transferred into congenically marked 
(CD45.2) wildtype mice, which were then infected with LCMV (DOCILE). Flow cytometric analysis 
of CXCR5 expression on P14 cells at day 8 p.i. Each symbol represents one mouse, bars 
represent means. **P < 0.01, as calculated by Mann-Whitney U-test. 
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Figure S3: The expression of CXCR5 on OT-I cells after infection or immunization. 
(A) OT-I cells (CD45.2) were adoptively transferred into congenically marked (CD45.1) wildtype 
mice, which were then intravenously infected with OVA-expressing influenza virus. Flow cytometric 
analysis of CXCR5 expression on OT-I cells in spleens at day 10 p.i.  
(B) OT-I cells (CD45.2) were adoptively transferred into congenically marked (CD45.1) wildtype 
mice, which were then immunized subcutaneously at hock with OVA in CFA. Flow cytometric 
analysis of CXCR5 expression on OT-I cells in popliteal lymph nodes at day 8 post immunization.  
Each symbol represents one mouse, bars represent means.  
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Figure S4: CD4+ T cells were significantly infected by LCMV (Docile). 
Intracellular staining of LCMV NP in splenic CD4+ T cells from uninfected, day 8 post OVA-
CFA immunization, day 8 p.i. with LCMV (WE) or LCMV (Docile) mice. Each symbol 
represents one mouse, bars represent means. **P < 0.01, as calculated by Mann-Whitney ’s 
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Figure S5: Higher infection in TFH cells than non-TFH cells. 
Eight mice were infected with LCMV (DOCILE). At day 15 p.i., TH subsets in spleens (gated 
as in Fig. 2B) were purified, pooled and infection was measured by qPCR. Data are 
representative of two independent experiments. Each symbol represents one experimental 
replicate, bars represent means. **P < 0.01, as calculated by Mann Whitney’s U-test.  
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Figure S6: Control of TFH infection by TFC cells. 
(A) Schematic of the experiment. (B) Quantification of  splenic TFH differentiation.  
(C) Quantification of P14 cells in spleens. (D) Viral loads in sera and spleens, as measured by 
plague forming assays. Data are representative of two independent experiments. Each symbol 
represents one mouse, bars represent means. N.S. , not significant  P > 0.05, as calculated by 
Mann Whitney’s U-test. 
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Figure S7: Expansion and activation of transferred CD8+ T cells in mice infected with MuHV-
4. 
(A) Representative FACS plots showing the total CD8 T cells with transferred cells marked by 
congenic marker CD45.1. (B) Quantification of transferred cells (left) or activated transferred cells 
(right) in total CD8+ T cells. Data are representative of two independent experiments. Each symbol 
represents one mouse, bars represent means. N.S. , not significant  P > 0.05, as calculated by 
Mann Whitney’s U-test. 
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Supplementary figure 8 
Figure S8: Expression of CXCR5 on CD8+ T cells in mice that developed spontaneous B-cell 
lymphoma. Representative FACS plots showing the expression of CXCR5 on total CD8+ T cells in 
WT or BCL6tg/+ mice which develop B cells lymphomas between 200-500 days of age. Each 
symbol represents one mouse, bars represent means. **P < 0.01, as calculated by Mann Whitney’s 
U-test. 
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Figure S9: Transcriptomic analysis of TFC cells.  
CD45.1+ P14 cells were adoptively transferred into congenically marked (CD45.2) wildtype mice, 
which were then infected with LCMV (DOCILE). CXCR5+ TFC and CXCR5
- non-TFC P14 cells were 
sorted on day 8 p.i. and naïve P14 cells were subjected to RNA-seq.  
(A) The bi-mode distribution of the log10 expression values of genes (count 0 excluded) shows the 
separation of the two peaks when log10 raw count is about 2.  Genes with raw counts lower than 
100 are considered as low/non-expressed, and  filtered out for signature gene sets. 
(B) Scatter plot of the normalized log2 data for all the 39,179 genes in CXCR5
- non-TFC (y axis) 
against CXCR5+ TFC (x axis). Yellow is for the genes that are low/non-expressed in both groups 
(29,423). Among 9,756 expressed genes, grey is for the genes that are not differentially expressed, 
red for the up-regulate genes (650), and blue for the down-regulated genes (551). 
(C) A heatmap for normalized log2 data of the top 500 list of genes that have the largest variance 
across all 8 samples. The two-dimensional clustering is shown.  
Supplementary figure 10 
Naïve    non-TFC              TFC 
Figure S10: The top 50 up- and down-regulated genes between TFC and non-TFC cells.  
Heatmaps for normalized log2 data of the top 50 lists of upregulated (A) or downregulated (B) 
genes. 
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Figure S11: The expression of inhibitory receptors on TFC cells. 
CD45.1+ P14 cells were adoptively transferred into congenically marked (CD45.2) wildtype mice, 
which were then infected with LCMV (DOCILE). The expression of indicated proteins in naïve 
(grey), CXCR5+ TFC (red), CXCR5- non-TFC (blue), B220
+ B (black) cells at day 8 p.i.  
(A) The expression of inhibitory receptors on TFC cells. 
(B) The expression of ICOSL on TFC cells.  
(C) IL-21-GFP reporter mice were infected with LCMV Docile and the expression of IL-21-GFP in 
indicated populations were analysed at day 15 p.i.. 
(D) Ex vivo killing of LCMV GP33-41 peptide-pulsed non-TFH or TFH SMARTA cells, or B cells by 
CXCR5+ TFC or CXCR5
- non-TFC P14 cells purified at day 8 p.i.  
Each symbol represents one mouse (A, B and D) or one sample (C), bars represent means. GMFI: 
geometric mean fluorescence intensity. Data are representative of two independent experiments. 
**P < 0.01, as calculated by Mann-Whitney’s  U-test. 
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Figure S12: The expression of transcriptional regulators in TFC cells. 
(A, B) Mice were infected with LCMV (Docile) Expression of transcriptional regulators Bcl6, Tcf1, 
Id3, and Blimp1 and Id2 as determined using intracellular staining (Bcl6 and Tcf1) or GFP reporter 
(Id3, and Blimp1 and Id2) in naïve (grey), CXCR5+ TFC (red) and CXCR5
- non-TFC (blue) cells at 
day 8 p.i.  Relative expression was calculated using GMFI divided by the average GMFI value of 
naïve population.  
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Figure S13: Enrichment analysis of the differentially expressed genes in TFC cells 
Gene set enrichment test of genes differentially expressed in TFC cells as compared to non-TFC 
cells in differentially expressed genes in TFH cells as compared to non-TFH cells (A), in Blimp1-
deficient TC cells (B), Id3-deficient TC cells (C) and Id2-deficient TC cells (D) as compared to 
counterpart wildtype TC cells. Red and blue bars designate up and down-regulated genes in TFC 
cells, respectively. Correlation of up (top) and down (bottom)-regulated genes were shown by 
rotation gene set test P values and the percentages.  
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Figure S14: Bcl6 regulates the phenotype and function of TC cells. 
P14 cells were transduced with a GFP retroviral empty vector (RV) or the vector expressing Bcl6. 
GFP+ transduced cells were purified. 
(A, B) Transduced cells were transferred into congenically marked recipient mice which were 
subsequently infected with LCMV (DOCILE). At day 8 p.i., the expression of indicated proteins on 
transduced cells was measured by flow cytometry.  
(C) Transduced cells were co-cultured with LCMV gp33-41 peptide-pulsed splenocytes and the killing 
of target cells were measured by flow cytometry.  
(D) Transduced cells were isolated and the indicated genes were measured by quantitative PCR. 
Each symbol represents one mouse or sample, bars represent means. Data are representative of 
two independent experiments. *P < 0.05, **P < 0.01, as calculated by Mann Whitney’s U-test. 
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Supplementary figure 15 
Figure S15: Correlation between transcription factor-bound genes and TFC signature genes. 
Gene set enrichment test of genes bound by Bcl6 (A), Blimp1 (B), E2A  (C) or Tcf1 (D) among 
transcripts differentially expressed in TFC cells versus non-TFC cells. Red and blue bars designate 
upregulated and downregulated genes in TFC cells, respectively. Significant correlation of binding 
sites (barcode plots) with differentially expressed genes is shown by P value. Percentages show 
proportion of genes bound by each transcription factor that were also differentially expressed in TFC 
vs non-TFC.  
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Figure S16: Regulation of Blimp1- and E2A-binding sites in the Cxcr5 locus. 
(A) Genomic sequences of the Cxcr5 genes that contain conserve putative Blimp1- or E2A-binding 
sites in indicated species. Mutant binding motifs used in reporter assays were indicated. 
(B) The schematics of the retroviral vector used for in vivo reporter assays SIN: self-inactivating; P: 
promoter. 
(C, D) P14 cells were transduced with Thy1.1-reporter constructs and GFP+ cells were injected into 
congenically marked recipient mice followed by LCMV (DOCILE). Plots showing the representative 
Thy1.1 expression on TFC and non-TFC cells at day 8 p.i. Percentages of Thy1.1
+ and Thy1.1 GMFI 
in Thy1.1+ cells are shown.  
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Figure S17: Binding of Blimp1 and E2A at the indicated genes. ChIP-seq analysis of Blimp1 
and E2A binding was performed with CD8+ effector T cells and total thymocytes, respectively. 
Binding regions, which were identified by MACS peak calling, are indicated by black rectangles 
below the horizontal axis. RPM: Reads per million 
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Figure 18: A working model of the differentiation and function of TFC cells.  
In persistent viral infections, TC cells upregulate CXCR5 to enter B cell follicles and eradicate 
infected cells. Blimp1 and E2A directly bind to the Cxcr5 gene locus to regulate its 
transcription. The differentiation of the TFC population requires the transcription factors Bcl6, 
E2A and Tcf1 (green), whereas the transcriptional regulators Blimp1, Id3 and Id2 (red) inhibit 
their development. Together, these regulators form a transcriptional circuit that controls the 
expression of CXCR5 and directs the differentiation of TFC cells. 
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Supplementary table 1 
Lymph node biopsies for immunofluorescent staining: 
Patient ID Gender HIV Status 
Date of Positive 
HIV Test 
Biopsy Date Age at biopsy 
Years infected 
at Biopsy 
CD4 count at 
Biopsy 
(cells/mm3) 
pVL at Biopsy 
(copies/mL) 
2391 F Negative NA 3/15/2006 52 NA 837 NA 
2918 M Negative NA 11/22/2010 63 NA NA NA 
2966 M Negative NA 1/20/2011 40 NA NA NA 
3491 F Negative NA 8/16/2012 53 NA NA NA 
3820 M Negative NA 1/7/2014 20 NA 693 NA 
3821 M Negative NA 1/7/2014 58 NA NA NA 
                  
2257 M Positive 12/1/2003 3/8/2004 27 0.27 1,058 2,620 
3447 M Positive 10/1/2001 5/10/2012 57 10.61 560 9,800 
3859 M Positive 6/1/2011 2/10/2014 30 2.69 445 24,400 
2210 F Positive 1/1/1987 12/5/2002 43 15.93 532 167 
2262 M Positive 12/1/2003 3/8/2004 27 0.27 845 2,080 
2414 M Positive 7/18/2005 2/14/2007 30 1.57 60 4,100 
3664 M Positive 1/2/2013 3/7/2013 21 0.18 1,007 698 
3709 M Positive 9/5/2013 9/26/2013 30 0.06 453 118,000 
3142 M Positive ND 6/2/2011 24 4* 570 62,900 
3504 F Positive 4/17/2012 9/12/2012 53 0.40 222 34,500 
3620 M Positive 9/24/2012 12/6/2012 61 0.20 335 2,100 
5115 M Positive 1/1/1982 12/9/2015 46 33.94 NA NA 
Lymph node biopsies for flow cytometry analysis: 
828063 M Positive NA 5/10/2016 23 NA 394 53218 
828315 M Positive NA 5/10/2016 48 NA 128 118187 
836748 M Positive NA 6/13/2016 42 NA 660 245526 
843486 M Positive NA 6/14/2016 56 NA NA ND 
*Estimated time infected 
ND, not determined 
Table S1: Demographic and haematological characteristics of 
HIV-infected and control subjects. 
